Welcome to our dedicated page for Creative Med Technology Hldgs news (Ticker: CELZ), a resource for investors and traders seeking the latest updates and insights on Creative Med Technology Hldgs stock.
Creative Medical Technology Holdings Inc. (CELZ) is a biotechnology innovator advancing stem cell therapies for sexual health, chronic pain, and endocrine disorders. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and strategic partnerships driving the company’s regenerative medicine pipeline.
Access verified press releases and news articles covering CELZ’s research progress, including updates on its hypoimmune iPSC platform, AlloStem therapies, and licensing agreements. Content spans clinical trial results, intellectual property announcements, and collaborations in AI-driven drug discovery.
Key updates include advancements in non-invasive treatments for erectile dysfunction, infertility solutions, and chronic pain management protocols. Users will find essential information on FDA communications, trial design approvals, and peer-reviewed study publications.
Bookmark this page for centralized access to CELZ’s latest innovations in cellular therapy. Check regularly for objective reporting on developments impacting the company’s position in regenerative medicine markets.
Creative Medical Technology Holdings (NASDAQ: CELZ) will showcase its patented CaverStem® procedure at the American Urological Association Annual Meeting on May 13-16, 2022, in New Orleans. This procedure utilizes patients' own stem cells to effectively treat erectile dysfunction. The company highlights landmark clinical trial results published in the Journal of Translational Medicine, demonstrating strong efficacy without major adverse effects. CaverStem® has garnered a growing physician network and offers optimized protocols that reduce costs and streamline treatment.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced a Master Collaboration Agreement with the University of Miami to enhance the ImmCelz® Supercharged Autologous Immunotherapy Platform. This partnership aims to optimize the platform, involving adult stem cells to improve patients' immune response. The company is focusing on advancing therapies for conditions like stroke, type I diabetes, heart, liver, and kidney diseases. ImmCelz® is currently under FDA review for stroke clinical trials. The initiative seeks to accelerate research and clinical translation of promising results.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced positive two-year follow-up results from its StemSpine® pilot study, showcasing an 87% efficacy rate in treating chronic lower back pain with no serious adverse effects reported. The StemSpine® procedure utilizes a patient's own bone marrow aspirate, offering a promising non-surgical alternative. The company plans to publish this data and present it at upcoming conferences. Positive engagement with physicians is expected, particularly at the American Academy of Orthopaedic Surgeons conference in Chicago.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced an exclusive agreement with Cervos Medical for the distribution of Marrow Cellution™ devices in urology, gynecology, and sexual dysfunction. This partnership grants Creative access to advanced regenerative therapies such as CaverStem® and FemCelz®. CEO Timothy Warbington highlighted the advantages of the agreement, including a strong supply chain and intellectual property. Cervos Medical's President emphasized the collaboration's potential to improve patient outcomes using innovative stem cell solutions.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced its participation in the 34th Annual Roth Conference from March 13-15, 2022, in Dana Point, California. The company specializes in regenerative approaches in immunotherapy, urology, neurology, and orthopedics. Executives will be available for one-on-one meetings during the event. For more details or to register, visit the conference's registration page. The latest investor presentation can be found on the company's IR website.
Creative Medical Technology Holdings (NASDAQ: CELZ) announced the appointment of Sahil Nock as its Chief Commercial Officer, effective February 28, 2022. Mr. Nock brings over 15 years of healthcare leadership experience, previously serving as Head of US Commercial Marketing at Mentor, and has a strong background in marketing and business development. President and CEO Timothy Warbington expressed confidence that Nock will significantly impact the company's regenerative medicine programs, including CaverStem®, FemCelz®, and StemSpine®.
Creative Medical Technology Holdings announced a public offering of 3,875,000 shares and warrants at $4.13, aiming for gross proceeds of approximately $16 million. The stock will be listed on the Nasdaq under the ticker CELZ starting December 3, 2021, with closure expected around December 7, 2021. Roth Capital Partners is leading the offering, which includes a 45-day option for underwriters to purchase additional shares. This funding is pivotal for the company's focus on regenerative treatments in immunology, urology, neurology, and orthopedics.
Creative Medical Technology Holdings, Inc. (OTC-CELZ) announced a 1-for-500 reverse stock split, effective November 10, 2021, to facilitate its planned listing on The Nasdaq Capital Market. The reverse split will reduce outstanding shares from 1,226,141,742 to 2,452,348 without altering stockholder equity percentages. The temporary ticker symbol during this process will be CELZD, reverting to CELZ upon Nasdaq listing. The company aims to enhance its visibility and shareholder value through this strategic move.
Creative Medical Technology Holdings Inc. (OTC-CELZ) announced promising proof of concept data for its ImmCelz™ immunotherapy. This innovative product, utilizing a patent-pending 'ex vivo cell-free' reprogramming protocol, shows potential to reprogram patient immune cells effectively. The study, conducted at the University of Miami, indicates ImmCelz™ may enable rapid clinical translation, aiming to suppress harmful immune responses associated with autoimmune diseases. The company has filed an IND with the FDA related to stroke treatment. The autoimmunity market is valued in the billions, highlighting significant growth potential.
Creative Medical Technology Holdings (OTC – CELZ) announced the filing of a new patent for nanoparticles known as 'exosomes' derived from its MyeloCelz™ platform, aimed at treating type 1 diabetes. The patent includes the use of these exosomes in combination with other agents promoting immunological tolerance.
Notable experts, including Dr. Camillo Ricordi, praised the innovation, highlighting the potential to specifically target harmful T cells without affecting the body's defenses. This advancement could revolutionize treatment for type 1 diabetes and related autoimmune diseases.
